Clinical trials: Coronavirus Infection
Anogenital Herpes, COVID-19
Viral Infections in Healthy and Immunocompromised Hosts
Background: Viral infections are an important cause of illness and death in hospitalized patients as well as outpatients. New strains of viruses may appear and infect both healthy people and those with weak immune systems.
- Conditions
- Anogenital Herpes, COVID-19, Herpes Labialis
- Trial name
- NCT01306084
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
This phase 1 randomized, open-label, dose-escalation clinical trial evaluates the safety and immunogenicity of OCU500, a ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine, in healthy adults aged 18-64 who previously completed a…
- Trial name
- NCT07536308
- Testing
- OCU500
- Where
- 6 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, SARS-CoV2
Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers
The purpose of this clinical trial is to determine the efficacy of Previfenon® (EGCG) to prevent COVID-19, enhance systemic immunity, and decrease the frequency and intensity of selected symptoms when used as pre-exposure…
- Trial name
- HERD (NCT04446065)
- Testing
- Previfenon®
- Volunteers
- healthy volunteers welcome
- Sponsor
- MELISA Institute Genomics & Proteomics Research SpA
COVID -19
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of RVX-sCPD9, given Intranasally (IN), as a booster dose to previously vaccinated healthy adults.
- Trial name
- NCT07703475
- Testing
- RVX-sCPD9
- Where
- 4 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations
The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1283 and mRNA-1273 (variant formulations) within the current epidemiological environment
- Trial name
- NCT07863635
- Testing
- mRNA-1273, mRNA-1283
- Where
- 5 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS-CoV-2
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)
The purpose of this study is to evaluate the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID-19.
- Trial name
- NCT07266558
- Testing
- mRNA-1273, mRNA-1283
- Where
- 150 sites in United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19 Vaccines
A Study of COVID-19 Vaccine(s) in Children and Adults
The purpose of this study is to learn about the safety and effects of updated COVID-19 vaccines (called BNT162b2) in participants 5 Through 64 Years of Age with risk factors for Severe COVID-19, and Participants 65 Years of Age…
- Trial name
- NCT07798648
- Testing
- BNT162b2
- Where
- 14 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Gut Microbiome, Gastrointestinal Microbiome
A Study to Explore the Role of Gut Flora in COVID-19 Infection
This study seeks to determine whether the virus which causes COVID-19, SARS-CoV-2, is shed in the stools of patients who are infected.
- Conditions
- Gut Microbiome, Gastrointestinal Microbiome, COVID, COVID-19
- Trial name
- NCT04359836
- Testing
- There is no intervention in this study
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- ProgenaBiome
Reside Either in Retirement Home or Long-term Care Units
Evaluation of Covid-19 Vaccination in Elderly Subjects in Retirement Home (EHPAD) and Long-term Care Units (USLD) in Ile-de-France
The main objective of this non-interventional, multi-center study is to compare the incidence of serious health events (death, unscheduled hospitalizations) in subjects vaccinated against Coronavirus with that of unvaccinated…
- Trial name
- COGEVAX (NCT04900376)
- Where
- France
- Volunteers
- 3,309 people, healthy volunteers welcome
- Sponsor
- Gérond'if
COVID19, COVID-19
At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study
Radish Health and ProofPilot in coordination with Sanesco are running this study to help establish whether the Premier Biotech COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma Authorized for distribution under…
- Conditions
- COVID19, COVID-19, Coronavirus
- Trial name
- NCT04393961
- Testing
- Premier Biotech COVID-19 IgG/IgM Rapid test Cassette
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- ProofPilot
SARS-CoV Infection, Covid19
KIDney Injury in Times of COVID-19 (KIDCOV)
There is an unmet need to evaluate the impact of sub-clinical/mild COVID19 disease in the outpatient setting on prevalent and incident renal injury, as this data is currently unavailable.
- Conditions
- SARS-CoV Infection, Covid19, Corona Virus Infection, Acute Kidney Injury
- Trial name
- KIDCOV (NCT04705766)
- Testing
- Urine Collection
- Where
- 3 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Coronavirus
First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers
This first-in-human clinical trial is designed to evaluate the safety and immunogenicity of one administration of OVX033 coronavirus vaccine at different dose levels (100µg, 250µg and 500µg)
- Trial name
- NCT06128382
- Testing
- OVX033, Saline solution
- Where
- France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Osivax
Influenza, Respiratory Virus
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
Background: Respiratory viruses circulate throughout the year and around the globe. Wearable and sensor devices, like smartwatches, may be able to help monitor infectious diseases.
- Conditions
- Influenza, Respiratory Virus, Coronavirus
- Trial name
- NCT04772170
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
This study will evaluate 2 dose levels of mRNA-1283 in participants ≥6 months to <12 years to determine the optimal dose level per age group.
- Trial name
- NCT07808697
- Testing
- mRNA-1283, mRNA-1273
- Where
- 31 sites in United States, Argentina and 4 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Isotretinoin Adverse Reaction, Covid19
Oral Isotretinoin and Covid-19 Infection
There is a theoretical risk that the nasal mucosal dryness caused by oral retinoid medications may increase risk of infection with Covid-19.
- Trial name
- NCT04663906
- Where
- United Kingdom
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- University of Aberdeen
COVID-19, SARS-CoV-2 Infection
A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19
The purpose of this study is to characterize the safety and immunogenicity of AZD9838 and AZD6563 when administered as a single dose vaccination against SARS-CoV-2 in adults.
- Trial name
- ARTEMIS-C (NCT06147063)
- Testing
- AZD9838, Licensed SARS-CoV-2 mRNA vaccine, AZD6563
- Where
- 5 sites in United States
- Volunteers
- 243 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose…
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension
- Trial name
- POPS or POP02 (NCT04278404)
- Testing
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Duke University
Corona Virus Infection, COVID
Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic
Prospective nationwide cohort study of pregnant women enrolled early in gestation and followed for Covid-19 exposure and infection, with follow up of obstetrical outcomes and infant development through the first year of life.
- Conditions
- Corona Virus Infection, COVID, Pregnancy Related, Early Pregnancy
- Trial name
- ASPIRE (NCT04388605)
- Where
- United States
- Volunteers
- 7,965 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Healthy Volunteers
CDI-988 Safety Study in Healthy Participants
The goal of this clinical trial is to learn about the safety and pharmacokinetics (PK, the amount of drug in the blood) of a new drug called CDI-988 in healthy volunteers.
- Trial name
- NCT05977140
- Testing
- CDI-988
- Where
- Australia
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Cocrystal Pharma, Inc.
COVID-19, SARS-CoV-2 Infection
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
The goal of this clinical trial is to test two investigational COVID-19 booster vaccines, called CoTend-s3BXBB and CoTend-BXBB, in healthy volunteers ages 40-64.
- Trial name
- CONTENDER (NCT06810934)
- Testing
- CoTend-BXBB (SARS2-30404), CoTend-s3BXBB (SARS2-17032)
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Kara Chew